These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16426732)

  • 1. Tachykinins: role in detrusor overactivity?
    Andersson KE
    Eur Urol; 2006 Mar; 49(3):423-5. PubMed ID: 16426732
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of ischemia on tachykinin-containing nerves and neurokinin receptors in the rabbit bladder.
    Azadzoi KM; Radisavljevic ZM; Siroky MB
    Urology; 2008 May; 71(5):979-83. PubMed ID: 18314167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tachykinins and tachykinin receptors in bone.
    Goto T; Tanaka T
    Microsc Res Tech; 2002 Jul; 58(2):91-7. PubMed ID: 12203708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The postmenopausal bladder.
    Tapp AJ; Cardozo L
    Br J Hosp Med; 1986 Jan; 35(1):20-3. PubMed ID: 3955284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tachykinin NK-2 receptor antagonist SR48968 does not block noncholinergic contractions in unstable human bladder.
    Moore KH; Lam DS; Lynch W; Burcher E
    Peptides; 2002 Jun; 23(6):1155-60. PubMed ID: 12126745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tibial neuromodulation in the treatment of neurogenic detrusor hyperactivity in patients with Parkinson's disease].
    Krivoborodov GG; Gekht AB; Korshunova ES
    Urologiia; 2006; (4):3-6. PubMed ID: 17058670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
    Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
    Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ; Lemack GE; Foote JE; Trop CS
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of the effects of rat/mouse hemokinin-1 on mouse colonic contractile activity: a comparison with substance P.
    Kong ZQ; Han M; Yang WL; Zhao YL; Fu CY; Tao Y; Chen Q; Wang R
    Neuropeptides; 2009 Jun; 43(3):213-20. PubMed ID: 19394690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of the stimulant actions of neurokinin a and human hemokinin-1 on the human uterus: a comparison with histamine.
    Pennefather JN; Patak E; Ziccone S; Lilley A; Pinto FM; Page NM; Story ME; Grover S; Candenas ML
    Biol Reprod; 2006 Sep; 75(3):334-41. PubMed ID: 16707771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity (Urology 68:1193-1197, 2006).
    Kadi N
    Urology; 2008 Oct; 72(4):951-2. PubMed ID: 18926254
    [No Abstract]   [Full Text] [Related]  

  • 12. Tachykinins are involved in local reflex modulation of vagally mediated striated muscle contractions in the rat esophagus via tachykinin NK1 receptors.
    Shiina T; Shimizu Y; Boudaka A; Wörl J; Takewaki T
    Neuroscience; 2006 May; 139(2):495-503. PubMed ID: 16458437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity?
    Ruffion A; Capelle O; Paparel P; Leriche B; Leriche A; Grise P
    BJU Int; 2006 May; 97(5):1030-4. PubMed ID: 16643486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
    Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concepts in characterization of tachykinin receptors.
    Burcher E; Mussap CJ; Geraghty DP; McClure-Sharp JM; Watkins DJ
    Ann N Y Acad Sci; 1991; 632():123-36. PubMed ID: 1719861
    [No Abstract]   [Full Text] [Related]  

  • 16. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
    Sahai A
    BJU Int; 2006 Feb; 97(2):413. PubMed ID: 16430657
    [No Abstract]   [Full Text] [Related]  

  • 17. Urodynamic distinctions between idiopathic detrusor overactivity and detrusor overactivity secondary to multiple sclerosis.
    Lemack GE; Frohman EM; Zimmern PE; Hawker K; Ramnarayan P
    Urology; 2006 May; 67(5):960-4. PubMed ID: 16635509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overactive bladder: defining the disease.
    Wein AJ
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S559-64; discussion S607-19. PubMed ID: 11183898
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of tachykinins and guanethidine on the acetylcholine output stimulated by nicotine from guinea-pig bladder.
    Shinkai M; Takayanagi I
    Jpn J Pharmacol; 1992; 58 Suppl 2():303P. PubMed ID: 1507565
    [No Abstract]   [Full Text] [Related]  

  • 20. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease.
    Ransmayr GN; Holliger S; Schletterer K; Heidler H; Deibl M; Poewe W; Madersbacher H; Kiss G
    Neurology; 2008 Jan; 70(4):299-303. PubMed ID: 18209204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.